Treatment for Hypercholesterolemia with Elevated LDL and Hypertriglyceridemia

Initial Assessment and Treatment Selection

The American Diabetes Association recommends that patients with elevated LDL cholesterol (above 100 mg/dL) should be started on atorvastatin 10-20 mg daily as first-line therapy, as this patient has an LDL level of 149 mg/dL 1, 2
The patient's triglyceride level (138 mg/dL) is mildly elevated but below the threshold that would require specific triglyceride-focused therapy (typically >200 mg/dL), according to the American Diabetes Association 1
HDL cholesterol is adequate at 51 mg/dL (>40 mg/dL is considered protective), as stated by the American Diabetes Association 1

The American Heart Association recommends starting with atorvastatin 10-20 mg daily for patients with elevated LDL and hypertriglyceridemia, as it is effective for both LDL reduction (35.7%-52.2% reduction depending on dose) and can help lower triglycerides 1, 2
For patients who do not achieve their LDL goal after 4-6 weeks, the American College of Cardiology recommends increasing the atorvastatin dose up to 40 mg daily and rechecking the lipid panel 4-6 weeks after dose adjustment 1
If the target is still not achieved, the European Society of Cardiology suggests considering adding ezetimibe 10 mg daily, which can provide an additional 15-20% LDL reduction 4

For patients with diabetes, the American Diabetes Association recommends an LDL goal of <100 mg/dL, with consideration of more aggressive targets (<70 mg/dL) for those with established cardiovascular disease 1, 3
If triglycerides increase to >200 mg/dL on follow-up, the American Heart Association recommends considering increasing the statin dose or adding a fibrate (fenofibrate preferred over gemfibrozil due to lower risk of myopathy when combined with statins) 1, 5
For patients with chronic kidney disease, the National Kidney Foundation recommends adjusting dosing appropriately 6

The American College of Cardiology advises against starting with too low a dose of statin in patients who need significant LDL reduction, and against combining gemfibrozil with statins due to increased risk of myopathy 1, 7
The European Society of Cardiology recommends not using bile acid sequestrants as first-line therapy due to poor tolerability and potential drug interactions, and not delaying treatment in patients with significantly elevated LDL cholesterol 4, 5
The American Heart Association suggests avoiding the use of niacin as first-line therapy due to its side effect profile (flushing, hyperglycemia) 5, 7